La catena delle opzioni mostra i dati chiave delle opzioni azionarie di  a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ..

 (OTC:ITIPF) Azioni, Catena delle Opzioni

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.brightview.com%2F&amp;esheet=54284695&amp;newsitemid=20250701254154&amp;lan=en-US&amp;anchor=BrightView&amp;index=1&amp;md5=02cf15c1332e5249f3e6cbcaa28ff655">BrightView</a> Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) (the "Company" or "BrightView"), the leading commercial landscaping services company in the United States, today updated its financial guidance for fiscal year 2025.
UPDATED FISCAL YEAR 2025 GUIDANCE
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">Updated Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue</td>
<td colspan="1" rowspan="1">$2.75B to $2.84B</td>
<td colspan="1" rowspan="1">$2.68B to $2.73B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$345M to $365M</td>
<td colspan="1" rowspan="1">$348M to $362M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin</td>
<td colspan="1" rowspan="1">+80bps to +110bps</td>
<td colspan="1" rowspan="1">~ 130bps+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Free Cash Flow1</td>
<td colspan="1" rowspan="1">$50M to $70M</td>
<td colspan="1" rowspan="1">$60M to $75M</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

BrightView Holdings Announces Updated Financial Guidance For FY25. Revenue Guidance Updated From $2.75B-$2.84B To $2.68B-$2.73B

Greenbrier Companies Affirms FY2025 Sales Guidance of $3.15B-$3.35B vs $3.22B Est

Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) (the "Company"), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement with accredited investors on the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock and Common Warrants. The offering was priced at the market under Nasdaq rules.
The offering consists of the sale of an aggregate of 2,382,084 shares of Common Stock (or Pre-funded Warrants in lieu thereof), 3,573,130 shares of Series B Convertible Preferred Stock and 6,355,214 Common Warrants. The Pre-Funded Warrants will be immediately exercisable at an exercise price of $0.00001 and may be exercised at any time until exercised in full. The initial exercise price of each Common Warrant is $1.00 per share of Common Stock. The Common Warrants are exercisable immediately and expire 60 months after the resale registration statement registering the underlying shares is declared effective.
Aggregate gross proceeds to the Company are expected to be approximately $5.0 million, $4.0 million of which will be paid at closing and $1.0 million of which will be paid when the resale registration statement registering Common Stock and the underlying shares is declared effective. The transaction is expected to close on or about July 2, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Offerings

LIXT

Lixte Biotechnology Raises ~$5M Through Sale Of 2.38M Common Shares, 3.57M Preferred Shares, and 6.36M Warrants

Asset Sales

BMRC

CORRECTION: Bank of Marin Bancorp Sold Book Value Of $186M Of AFS Securities

Earnings

Earnings Beats

Greenbrier Companies Q3 EPS $1.86 Beats $0.98 Estimate, Sales $842.70M Beat $785.72M Estimate

Meiwu Technology Company Limited Engages Shenzhen Zhinuo Weichuang Technology Co. For Its Marketing Services From Jul. 1, 2025 To Jun. 30, 2026

Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares are trading higher on Tuesday after Wells Fargo raised its price target on the stock from $8 to $11, citing stronger-than-expected revenue growth in <a href="https://www.benzinga.com/m-a/25/06/46038952/snap-just-bought-a-student-calendar-app-how-it-could-reinvent-snapchat">a stabilizing ad market. </a>
What To Know: The firm now expects second-quarter revenue to increase 13% year-over-year, up from a prior estimate of 6% and above the consensus forecast of 8%. Wells Fargo also sees subscription revenue reaching $165 million and forecasts $76 million in EBITDA for the quarter, nearly double the street estimate, <a href="https://www.investing.com/news/analyst-ratings/snap-stock-price-target-raised-to-11-from-8-at-wells-fargo-on-ad-growth-93CH-4118881">according to Investing.com.</a>
The bank highlighted growing optimism around the Sponsored Snaps feature, which monetizes the chat interface and could generate $400 million in revenue by 2027, with $20 million projected this quarter alone. 
While domestic user engagement continues to decline, daily active users in the U.S. and Canada are down 4%, international markets remain stable, growing 8% annually.
Snap has also made headlines with its upcoming public release of new AR glasses, Specs, in 2026, along with enhancements to its Snap OS operating system that integrate OpenAI and Google Cloud tools for AI-powered development. 
Additional analyst updates were mixed: Loop Capital cut its price target to $12 from $16 but maintained a Buy rating, and Benchmark reiterated its Hold rating while noting recent improvements in ad targeting tech and an expanding advertiser base.
The broader competitive landscape may also be helping Snap. 
TikTok, a key rival, is facing scrutiny from EU regulators for potential violations of the Digital Services Act and a $600 million privacy-related fine. The regulatory pressure on TikTok may indirectly benefit Snap's ad business as marketers reconsider platform risk.
SNAP Price Action: Snapchat shares closed up 7.59% at $9.35 at publication on Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46204187/palantir-stumbles-solar-stocks-rally-as-senate-approves-tax-bill-whats-moving-markets-tuesday">Palantir Stumbles, Solar Stocks Rally As Senate Approves Tax Bill: What&#8217;s Moving Markets Tuesday?</a></li>
</ul>
Image Via Shutterstock.

Social Media

Movers

Trading Ideas

SNAP

What's Going On With Snap Shares Today?

WIIM

DFDV

DeFi Development shares are trading lower after the company announced plans for a $100 million convertible notes offering.

Cue Biopharma shares are trading higher after the company provided updates and highlighted data for CUE-101.

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 8.38% on an annualized basis producing an average annual return of 22.65%. Currently, Spotify Technology has a market capitalization of $148.12 billion. 
Buying $100 In SPOT: If an investor had bought $100 of SPOT stock 5 years ago, it would be worth $277.55 today based on a price of $722.35 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751400921_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPOT

$100 Invested In Spotify Technology 5 Years Ago Would Be Worth This Much Today

Wabtec Finalizes Acquisition of Evident's Inspection Technologies Division For $1.78B

General

ALTS

ALT5 Sigma Added As A Member Of The Russell Microcap Growth, Russell 3000E And Russell 3000E Growth Indexes

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company"), the first US public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2030 (the "Convertible Notes") in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also expects to grant the initial purchasers of the Convertible Notes an option to purchase, for settlement within a 13-day period beginning on, and including the date on which the Convertible Notes are first issued, up to an additional $25 million aggregate principal amount of the Convertible Notes.
The Company intends to use a portion of the net proceeds from the offering to repurchase shares of the Company's common stock, par value $0.00001 per share (the "common stock") through the prepaid forward described below.&nbsp; The Company expects to use the remainder of the net proceeds from the offering for general corporate purposes, including the acquisition of SOL.

DeFi Development Corp. Plans $100M Convertible Notes Offering To Fund Stock Buyback And Solana Acquisitions

Jefferies analyst Edison Lee upgrades Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Underperform to Hold and raises the price target from $170.62 to $188.32.

Upgrades

Price Target

Analyst Ratings

AAPL

Jefferies Upgrades Apple to Hold, Raises Price Target to $188.32

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) affirms FY2026 Adj EPS guidance from $12.60-$12.90 to $12.60-$12.90 vs $12.69 analyst estimate..

Constellation Brands Affirms FY2026 Adj EPS Guidance of $12.60-$12.90 vs $12.69 Est

ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months
BOSTON, July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=U6uZoiaYsN9XtZjW8KdVnHlrgRQAThJuaNXzmvQfRDT7p03ofum_3l56cvLb6Oo_K9BWGavjLtHwb3OdGUmh15kntbjvB2LfH98FVwP0XXRrotMkSJS3ZEeoga9tx-C66vQ7XfXQkufw1IfSY2s0ag97kHuBdgbRor2B1lwj3tJ2nCxTJhkKP6JfGOIo7BwwSw1W6qmMDVuMT7ETXAVIN29EUmGQRkT3sAH0UzSxu83wBMDW3KvhE_oeVXx8HIHmhm-CYhN2hMgRcc599LCSPg==">Cue Biopharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today provided an update on its most advanced clinical stage asset, CUE-101, representative of the CUE-100 series.
Dr. Dimitrios Colevas presented new data from the company's maturing Phase 1 trial evaluating CUE-101 in combination with KEYTRUDA&#xAE; (pembrolizumab) for patients with recurrent metastatic HPV+ head and neck squamous cell carcinoma (HNSCC). Data highlights include an overall response rate (ORR) of 50% (with 1 unconfirmed PR) in patients with combined positive score (CPS) &gt;1 and an ORR of 50% observed in patients with low CPS scores (1-19). This compares favorably to the historical ORR of 19% observed with pembrolizumab alone in the third-party KEYNOTE 048 trial. Notably, the 12-month overall survival (OS) of 88% in the Phase 1 trial represents a significant reduction in the risk of death (HR 0.23) compared to historical data from the KEYNOTE 048 study. The Kaplan-Meier (K-M) estimate for median overall survival (mOS) is currently 32 months.

Cue Biopharma Issues Update On Its Clinical Stage Asset, CUE-101, Representative Of CUE-100 Series; Data Highlights Include ORR Of 50% In Treatment-Naive Patients With HPV+ R/M HNSCC

<a href="https://www.globenewswire.com/Tracker?data=Kwadq9hGybbR4rqgXHlCISdNA55RyVG0qFRoVl_IBiaRnnVDNG7A4aVakfQujHaoDE94q3YtHKHigI1AZlgg_vsFv7dSh5RORHYo4bYSOtBmEhHNkgcxHdcZGWkz82RX">Eos Energy Enterprises, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced that it has received its second loan advance from the Department of Energy's (DOE) Loan Programs Office in the amount of $22.7 million. With this advance, the Company has fully drawn the maximum allowable amount under the first tranche of $90.9 million in connection with the completion of its first state-of-the-art manufacturing line.
The loan advance covers 80% of eligible costs, incurred as part of the Company's production expansion plans related to Project AMAZE. These funds support Eos' ongoing efforts to expand its operational capacity to meet growing customer demand and further its strategic growth objectives.

Financing

EOSE

Eos Energy Draws Full $90.9M DOE Loan Tranche To Boost U.S. Zinc Battery Production

Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) reported quarterly earnings of $3.22 per share which missed the analyst consensus estimate of $3.31 by 2.6 percent. This is a 9.8 percent decrease over earnings of $3.57 per share from the same period last year. The company reported quarterly sales of $2.515 billion which missed the analyst consensus estimate of $2.554 billion by 1.52 percent. This is a 5.52 percent decrease over sales of $2.662 billion the same period last year.

Earnings Misses

Constellation Brands Q1 Adj. EPS $3.22 Misses $3.31 Estimate, Sales $2.515B Miss $2.554B Estimate

VERO

Venus Concept Announces Exchanges $6.5M Of Subordinated Convertible Notes Held By Affiliates Of Madryn Asset Management, LP For 325,651 Shares Of Series Y Preferred Stock

ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.
Goldman Sachs &amp; Co. LLC, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

AVBP

ArriVent Announces Proposed $75M Public Offering Of Common Stock

BlackRock iShares USD TIPS 0-5 UCITS ETF USD (Dist)

Comments

(ITIPF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO